Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

nivolumab-relatlimab

- PMLiVE

Bristol Myers Squibb’s New Drug Application for mezigdomide accepted by FDA

Mezigdomide improves progression-free survival in patients with relapsed or refractory multiple myeloma

- PMLiVE

Bristol Myers Squibb and SystImmune announce phase 3 results for antibody-drug conjugate

The drug showed improvements in overall survival and progression-free survival in two cancers

- PMLiVE

Bristol Myers Squibb evolves and expands multiple myeloma programme

Created in 2016, the Standing in the Gaap programme aims to advance more equitable care

- PMLiVE

BMS’ Opdivo gets expanded FDA and EU approval for Hodgkin lymphoma

This type of cancer is the most common one diagnosed in teenagers

- PMLiVE

Bristol Myers Squibb’s Sotyktu approved by US FDA for psoriatic arthritis

Sotyktu is the first TYK2 inhibitor approved for active psoriatic arthritis

- PMLiVE

BMS announces affordable drug price agreement with US government

The company will provide Eliquis, its oral blood thinner, free of charge to Medicaid

- PMLiVE

BMS granted FDA priority review for Breyanzi in marginal zone lymphoma

The disease accounts for approximately 7% of all non-Hodgkin lymphoma cases

- PMLiVE

BMS and Bain Capital launch new company to develop immunology therapies

The newly formed company has in-licensed five investigational immunology drugs from BMS

- PMLiVE

BMS and BioNTech partner on solid tumour candidate in deal worth over $11bn

BioNTech’s BNT327 is being evaluated in multiple clinical trials, including phase 3 studies in first-line lung cancer

- PMLiVE

Bristol Myers Squibb’s perioperative Opdivo regimen granted EC approval in NSCLC

Up to 55% of patients with non-metastatic NSCLC develop recurrence despite curative resection

- PMLiVE

Johnson & Johnson’s bladder cancer therapy Balversa accepted by SMC

Almost 1,700 people are diagnosed with bladder cancer in Scotland annually

- PMLiVE

Bristol Myers Squibb’s injectable Opdivo formulation granted MHRA for solid tumours

The new formulation reduces administration time from 30-to-60 minutes to three-to-five minutes

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links